Clinical trial
Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In…
NCT00430781 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00430781 |
|---|---|
| Title | Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer |
| Official title | A Phase II, Open-Label, Randomized, Multicenter Trial of Pazopanib (GW786034) in Combination With Lapatinib (GW572016) Compared to Pazopanib Monotherapy and Lapatinib Monotherapy in Subjects With FIGO Stage IVB or Recurrent or Persistent Cervical Cancer With Zero or One Prior Chemotherapy Regimen |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasms, Uterine Cervix, Metastatic Cervical Cancer |
| Intervention type | Drug |
| Interventions | pazopanib (GW786034), lapatinib (GW572016) |
| Enrollment | 228 |
| Start date | Nov 1, 2006 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2011 |
| First posted | Feb 2, 2007 |
| Last update posted | May 8, 2015 |
| Countries | Argentina, Belgium, Canada, Estonia, France, Germany, India, Ireland, Italy, Mexico, Spain, Thailand and 1 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: